Superior Planning, LLC’s Design Therapeutics DSGN Stock Holding History

Superior Planning, LLC’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.27K	Buy	+260	New	+$3.59K	﹤0.01%	1371

Other funds holding DSGN

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Superior Planning, LLC's DSGN Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Design Therapeutics (DSGN) in Q3 2026: 260 shares worth $3.27K. The stake represents ﹤0.01% of the portfolio and ranks #1371 among its holdings.

68 funds tracked by Wall St. Rank hold DSGN as of Q3 2026.

Superior Planning, LLC held 260 shares of Design Therapeutics worth $3.27K as of Q3 2026.
Design Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Design Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1371 holding.
68 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.